What this study is
The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and to explore what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate). This study will also test whether or not regular exercise on a bicycle and/or treatment with 6R-BH4 (Kuvan) pills, or histidine and beta-alanine supplementation improves these measures during exercise. 6R-BH4 is currently FDA-approved for use in patients with certain forms of a disease called phenylketonuria, but it is not currently FDA approved for blood pressure or exercise capacity in people with CKD.
What's being tested
- 6R-BH4
Intervention · DRUG
Participants will receive 200 mg of 6R-BH4 twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
- 6R-BH4 placebo
Intervention · OTHER
Participants will receive a placebo that is identical to 200 mg of 6R-BH4. The placebo will be taken twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
- Folic acid
Intervention · DIETARY SUPPLEMENT
Participants will take 1 mg of folic acid daily for 12 weeks. Folic acid is given because it enhances the binding affinity of BH4 to nitric oxide synthase (NOS), and also enhances the regeneration of BH4 from inactive BH2
- Exercise training
Intervention · OTHER
Participants will exercise 3 times a week on a stationary ergometer. Exercise intensity will begin at low levels (50% of maximal heart rate reserve) calculated utilizing the Karvonen method. Briefly, target exercise heart rate (HR) is calculated by subtracting the persons age from 220. Resting heart rate is then subtracted from this number. The answer is then multiplied by the target percent (50% for example) and the product is added back to resting heart rate to provide the target exercise session heart rate. Intensity will be increased by 5% every week (as tolerated by the participant) to a maximum of 80% of maximal heart rate. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week.
- Stretching
Intervention · OTHER
Participants randomized to 'No Exercise Training' group will instead of aerobic exercise, undergo progressive whole body stretching and toning exercises designed for individuals 65 and older. This type of low intensity activity is designed not to increase heart rate and will serve as the Control group to the Exercise Training group. The Control group will come in for stretching sessions 3 times per week for 20-45 minutes.
- Histidine and beta-alanine supplementation
Intervention · DIETARY SUPPLEMENT
Histidine and beta-alanine are two over-the-counter supplements commonly used to enhance sports performance in athletes. Participants randomized to this study arm will receive combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.
- Histidine and beta-alanine placebo
Intervention · OTHER
Participants randomized to this study arm will receive a placebo to match combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.
Study details
- Official title
- Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease
- Sponsor
- Emory University
- Conditions
- Renal Insufficiency, Chronic
- Enrolling
- 150 people
- Starts
- 2016-10
- Est. completion
- 2027-04-30
- Design
- Single-blind, randomized, factorial, Phase 2
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 75 YearsSex ALLHealthy volunteers Not acceptedChronic Kidney Disease Patients
You may qualify if
- Stage III or IV Chronic Kidney Disease, defined as reduction in estimated glomerular filtration rate (eGFR) to 15-59 cc/minute as calculated by the modified Modification of Diet in Renal Disease (MDRD) Study equation or the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
- Stable renal function, with no greater than a 30% reduction in eGFR over the prior 3 months
- Does not exercise regularly (defined as exercising less than 20 minutes twice per week)
- Willing and able to cooperate with the study protocol
You can't join if
- Severe CKD (eGFR<15 cc/minute)
- Ongoing drug or alcohol abuse
- Diabetic neuropathy
- Any serious systemic disease that might influence survival
- Severe anemia with hgb level <9 g/dL
- Clinical evidence of congestive heart failure or ejection fraction below 35%
- Symptomatic heart disease determined by prior electrocardiogram, stress test, and/or history
- Treatment with central alpha agonists (clonidine)
- Uncontrolled hypertension with BP greater than 170/100 mm Hg
- Low blood pressure with BP less than 100/50
- Pregnancy or plans to become pregnant
- Current treatment with monoamine oxidase (MAO) inhibitors
- Inability to exercise on a stationary bicycle
Control Study Participants
You may qualify if
- Does not exercise regularly (defined as exercising less than 20 minutes twice per week)
- Willing and able to cooperate with the study protocol
You can't join if
- Severe CKD (eGFR<15 cc/minute)
- Ongoing drug or alcohol abuse
- Diabetic neuropathy
- Any serious systemic disease that might influence survival
- Severe anemia with hgb level <9 g/dL
- Clinical evidence of congestive heart failure or ejection fraction below 35%
- Symptomatic heart disease determined by prior electrocardiogram, stress test, and/or history
- Treatment with central alpha agonists (clonidine)
- Uncontrolled hypertension with BP greater than 170/100 mm Hg
- Low blood pressure with BP less than 100/50
- Pregnancy or plans to become pregnant
- Current treatment with monoamine oxidase (MAO) inhibitors
- Inability to exercise on a stationary bicycle
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (3)
3 openContact for every open site
- Dana DaCosta · Contact404-727-7762drdacos@emory.edu
- Jeanie Park, MD · Principal investigator
Emory University Hospital Midtown
Atlanta, Georgia, United States
RecruitingEmory University Hospital
Atlanta, Georgia, United States
RecruitingAtlanta VA Health Care System
Decatur, Georgia, United States
- Melanie Kankam · Contact404-321-6111 ext. 7040mljeffe@emory.edu
Recruiting
Study team
Sponsor
Emory University
Study ID IRB00091660
Principal investigator
Joe Nocera, PhD
Emory University
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.